Blincyto (Blinatumomab) is used for the treatment of patients with acute lymphoblastic leukemia (ALL).

BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adults and children with (1) B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. This indication is approved under accelerated approval based on MRD response rate and hematological relapse-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. (2) Relapsed or refractory B-cell precursor acute lymphoblastic leukemia

Blincyto (Blinatumomab) suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of Blincyto (Blinatumomab) brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Blincyto (Blinatumomab) medicine cost price in India.

The order for Blincyto (Blinatumomab) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Blinatumomab (trade name Blincyto) is a biopharmaceutical drug used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated approval program.

BLINCYTO®(blinatumomab) for injection, for intravenous use. Initial U.S. Approval: 2014

Generic Name: blinatumomab

For injection: 35 mcg of lyophilized powder in a single-dose vial for reconstitution

Blincyto (blinatumomab)

BLINCYTO® (blinatumomab) for injection, for intravenous use is available.

Get In Touch

Blincyto (Blinatumomab) suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Blincyto (Blinatumomab) on prescription and Import License in Patient's Name only.

For overseas patients, Blincyto (Blinatumomab) can be made available in Send your enquiry to find Blincyto (Blinatumomab) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for Blincyto (Blinatumomab).

For ALIMTA (pemetrexed disodium) Injection Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse For More Details

Blinatumomab Approved in Europe for MRD+ ALL For More Details